Condition of Approval Study (COAST)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This prospective, multicenter longitudinal five-year study of X-STOP PEEK usage in LSS patients is designed to supplement pre-market safety and effectiveness data with information on longer-term device performance in a population of patients with moderately impaired physical function at preoperative baseline (i.e., an "indicated" population) who elect to undergo X STOP PEEK surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Lumbar Spinal Stenosis |
Device: X-STOP PEEK |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Treatment of Lumbar Spinal Stenosis With X-STOP® PEEK Spacer in Moderately Symptomatic Patients |
- Treatment response rates equivalent to overall success reported in the IDE pivotal trial as measured by improvement in ZCQ scores, no additional surgery for LSS, maintenance of distraction, no dislodgement of the implant or device related complications. [ Time Frame: Two years ] [ Designated as safety issue: No ]
- Secondary endpoints: SF-36, ODI, and NRS scores, Adverse event rate,device failures, MRI evaluation of adjacent levels and secondary surgeries. [ Time Frame: Two to Five years ] [ Designated as safety issue: No ]
- Treatment response rates at 5 years as measured by ZCQ, no additional LSS surgery, maintenance of distraction, no dislodgement or device complications. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 240 |
| Study Start Date: | August 2007 |
| Estimated Study Completion Date: | July 2019 |
| Estimated Primary Completion Date: | July 2019 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: X-STOP PEEK
In this arm, patients will undergo X-STOP PEEK surgery.
|
Device: X-STOP PEEK
Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
|
Detailed Description:
This prospective, multicenter longitudinal five-year study of X-STOP PEEK implant usage in LSS patients is designed to supplement pre-market safety and effectiveness data with information on longer-term device performance in a population of patients with moderately impaired physical function at preoperative baseline (i.e., an "indicated" population) who elect to undergo X-STOP PEEK surgery. This post-approval study will enroll 240 patients at up to 8 clinical sites where all participating spine surgeons have completed a company-sponsored physician training program. The clinical sites recruited to participate in this study comprise a geographically diverse mix of academic, referral, and/or community based sites.
Safety and effectiveness data will be assessed at baseline and annually through five (5) years postoperatively. Office visits will be scheduled preoperatively, and at 6 weeks, 1, 2, 3, 4, and 5 years postoperatively. Clinical/neurological and radiographic examination will be performed during each office visit. A baseline patient history (including medication usage) will be taken, and concomitant medications will be recorded at each postoperative follow-up visit. In addition, patients will be asked to complete the following questionnaires prior to consultation with their physicians or their staff: Zurich Claudication Questionnaire (ZCQ), Oswestry Disability Index (ODI), Numeric Rating Scale (NRS), and SF-36 Health Survey. At the 2-, 3-, 4- and 5-year office visit, patients will also be asked two questions assessing the value of surgery and the overall improvement in the quality of life postoperatively.
The primary study endpoint in this study is treatment success. Secondary endpoints will include scores from the SF-36, ODI, and NRS, as well as incidence rates of adverse events, device failures, and secondary surgeries.
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- has a baseline score >2.0 in the Physical Function (PF) domain of the Zurich Claudication Questionnaire
- is 50 years old or older
- has leg/buttock/groin pain with or without back pain NOTE: Leg/buttock/groin pain must be completely relieved when flexed such as when sitting in a chair. If back pain is also present, it must be partially relieved when flexed.
- can sit for 50 minutes without pain
- can walk 50 feet or more
- has a confirmed diagnosis of neurogenic intermittent claudication secondary to lumbar spinal stenosis, with X-Ray, MRI and/or CT evidence of thickened ligamentum flavum, narrowed lateral recess and/or central canal narrowing
- has completed at least six months of conservative care therapy which may include but is not limited to physical therapy, bracing, systemic or injected medications
- has signed a patient informed consent document
- is physically and mentally willing and able or has a caregiver who can comply with the postoperative and routinely scheduled clinical and radiographic evaluations
- lives in the immediate area and has no plans to relocate to another geographic area before completion of the study or lives outside the immediate area and will comply with the scheduled postoperative visits with a prearranged and designated physician
Exclusion Criteria:
- has a baseline score less than or equal to 2.0 in the Physical Function (PF) domain of the Zurich Claudication Questionnaire
- cannot sit for 50 minutes
- cannot walk more than 50 feet
- has unremitting pain in any spinal position
- has axial back pain only without leg/buttock/groin pain
- has a fixed motor deficit
- has cauda equina syndrome defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction
- has severe symptomatic lumbar spinal stenosis at more than two levels
- has significant instability of the lumbar spine, e.g., isthmic spondylolisthesis or degenerative spondylolisthesis greater than grade 1 (on a scale of 1 to 4)
- has an ankylosed segment at the affected level(s);
- has significant scoliosis (Cobb angle is greater than 25 degrees)
- has an acute fracture of the spinous process or pars interarticularis
- has sustained pathologic fractures of the vertebrae or multiple fractures of the vertebrae and /or hips
- has severe osteoporosis of the spine or hip, defined as bone mineral density (BMD) in the spine or hip more than 2.5 SD below the mean of adult normals in the presence of one or more fragility fractures
- has Paget's disease at the involved segment(s) or metastasis to the vertebrae
- has had any surgery of the lumbar spine
- has significant peripheral neuropathy demonstrated by nerve conduction velocity tests
- has acute denervation secondary to radiculopathy, as shown by EMG
- has significant peripheral vascular disease characterized by diminished dorsalis pedus or tibial pulses
- has extreme obesity as defined by a Body Mass Index (BMI) greater than 40 kg/m2
- has an active systemic infection or infection localized to the site of implantation
- has an active systemic disease such as AIDS, HIV, hepatitis, etc.
- has a medical condition that may interfere with postoperative management and follow-up, or may result in patient death prior to study completion (e.g., Alzheimer's disease, unstable cardiac disease, active malignancy)
- has a recent history of narcotic abuse (i.e., within last 3 years)
- has a known allergy to titanium,titanium alloy, or polyetheretherketone
- is immunologically suppressed, or has received or is receiving steroids at any dose daily for more than one month within the last 12 months
- is currently involved in a study of another investigational product that may affect the outcome of this study
- is pregnant or planning to become pregnant during the study period
- cannot undergo MRI or tolerate closed MRI scanning.
Contacts and Locations| Contact: Clinical Department | 1800-876-3133 ext 6068 | msbkclinicalresearch@medtronic.com |
Show 28 Study Locations| Principal Investigator: | Jim Malcolm, MD | Pinnacle Orthopedics |
More Information
Publications:
| Responsible Party: | Medtronic Spine LLC |
| ClinicalTrials.gov Identifier: | NCT00517751 History of Changes |
| Other Study ID Numbers: | LSS-006-COA |
| Study First Received: | August 15, 2007 |
| Last Updated: | April 23, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Medtronic Spine LLC:
|
Lumbar Spinal Stenosis X-STOP Spacer Interspinous process decompression Neurogenic Intermittent Claudication |
Additional relevant MeSH terms:
|
Constriction, Pathologic Spinal Stenosis Pathological Conditions, Anatomical |
Spinal Diseases Bone Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on June 18, 2013